October 16, 2019
Editor's Note: This story has been updated with additional quotes from Pear Therapeutics.
The poster child of digital therapeutics-pharma collaborations is soon to be no more, as Novartis division Sandoz announced that it is handing sole responsibility for the commercialization of the reSET and reSET-O prescription digital therapeutics back to Pear Therapeutics.
“Pear and Sandoz previously signed...
October 1, 2019
Novartis is teaming up with Microsoft on a new artificial intelligence initiative focused on drug discovery and development. The new efforts will primarily be focused in Novartis’ newly announced AI innovation lab.
As part of the deal Novartis will be employing Microsoft’s AI tools to help its scientist with computational hurdles in life sciences including generative chemistry, image...
September 12, 2019
Fifteen startups providing solutions to help people with dementia or frailty and to improve the delivery of primary care and outpatient services, as well as prevention and public health, have been selected to take part in a new accelerator supported by the NHS and tech and pharma companies.
Launched by Up Ventures, MediaCityUK, Health Innovation Manchester, the Salford Royal NHS Foundation Trust...
September 6, 2019
Home to around 40 museums, including Fondation Beyerel, Basel is famous for its vibrant art scene. But for the past 250 years, the country’s third largest city has also established itself as a hotspot for chemical and pharma innovation. It hosts the headquarters of two of the largest pharma companies in the world, Novartis and Roche. In fact, two predecessor companies of Novartis, Sandoz and Ciba...
August 6, 2019
Increasingly, Amazon Alexa and Siri are no longer just a tool for ordering pizza. Voice technology has found its way into healthcare, and now one of the most established industries in the medical world is starting to explore the possibilities of voice: pharma.
“I think voice should be part of a robust ecosystem in which pharma provides treatment information … and things like that,” Kay Bayne,...
July 3, 2019
Diving deeper into digital, this quarter the pharma giants have continued to implement new tools to enhance clinical trials, support medication management with technology and partner in developing digital therapeutics.
Onc, a foreign entity to this established industry, pharma executives are now becoming better versed in working with digital health companies and sharing the lessons they've...
May 21, 2019
Cala Health, a wearable neuromodulation therapy startup focused on chronic diseases, has closed a $50 million Series C financing round.
Novartis, Baird Capital, LifeSci Venture Partners, TriVentures and other unnamed backers participated, as did returning investors JJDC, Lux Capital, Lightstone Ventures, Action Potential Venture Capital, dRx Capital and GV.
WHAT THEY DO
May 21, 2019
This morning Verily announced a series of new strategic partnerships with four global pharmaceutical companies that will bring low-burden digital data collection and analysis tools to clinical research projects.
Alongside Novartis, Otsuka, Pfizer and Sanofi, the Alphabet subsidiary will employ its Project Baseline platform to increase the number and diversity of study populations by making it...
May 9, 2019
Transplant clinics in Sweden will see digital health startup Pilloxa’s innovation be deployed in a new collaboration with Novartis division Sandoz Nordics to improve medication adherence, announced today.
Founded in 2015, Pilloxa has developed a platform that consists of an intelligent pillbox, an app and a cloud solution, along with data driven services, that aims to help patients take their...
March 4, 2019
Pharma giant Novartis and O2 innovation arm Wayra UK revealed last week that Virtue, TestCard and ExSeed would join its nine-month Health Hub accelerator programme.
“After a rigorous judging day, I believe the innovations these three startups offer will make a significant difference to patients and the NHS,” said Novartis Market Access Director Fiona Bride. “I look forward to supporting them over...